Encorium Group has acquired Progenitor Holdings AG, a Swiss CRO with subsidiaries in Mexico, Panama, Argentina, Chile, Switzerland, India and Hong Kong for cash and stock valued at $2.25 million, with earn-out consideration of cash and stock with a value of up to $2.1 million. Encorium’s chief executive pfficer Dr. Kai Lindevall remarked, “The acquisition of Progenitor will allow us to offer our clients access to the value of conducting clinical trials in emerging markets such as ...